Deutsche Bank AG Acquires 3,170 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Deutsche Bank AG grew its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 0.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 922,403 shares of the medical equipment provider's stock after purchasing an additional 3,170 shares during the period. Deutsche Bank AG owned approximately 0.46% of Zimmer Biomet worth $97,433,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Stonebridge Financial Group LLC acquired a new position in Zimmer Biomet in the fourth quarter worth approximately $25,000. Accredited Wealth Management LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter worth $36,000. Kentucky Trust Co acquired a new stake in shares of Zimmer Biomet during the fourth quarter worth $39,000. OFI Invest Asset Management acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at $40,000. Finally, Dunhill Financial LLC raised its holdings in Zimmer Biomet by 86.6% during the 4th quarter. Dunhill Financial LLC now owns 444 shares of the medical equipment provider's stock worth $47,000 after buying an additional 206 shares during the period. Institutional investors and hedge funds own 88.89% of the company's stock.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares of the company's stock, valued at $915,379.20. This trade represents a 14.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 1.39% of the company's stock.

Zimmer Biomet Stock Performance

NYSE:ZBH traded down $2.26 during mid-day trading on Wednesday, hitting $95.23. 3,550,377 shares of the company's stock traded hands, compared to its average volume of 1,741,414. The firm has a market capitalization of $18.84 billion, a price-to-earnings ratio of 21.40, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. The firm has a 50 day moving average of $104.14 and a two-hundred day moving average of $106.04. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 12 month low of $89.92 and a 12 month high of $122.17.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm's revenue for the quarter was up 1.1% compared to the same quarter last year. During the same period last year, the firm earned $1.94 EPS. On average, equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.01%. The ex-dividend date of this dividend was Monday, March 31st. Zimmer Biomet's payout ratio is presently 21.24%.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Royal Bank of Canada dropped their target price on shares of Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Truist Financial set a $101.00 price objective on shares of Zimmer Biomet in a research report on Tuesday, May 6th. Morgan Stanley reduced their target price on Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Raymond James dropped their price target on Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Finally, JMP Securities decreased their price objective on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $113.45.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.